A low dose Pimobendan was observed to prolong the period until re-hospitalization for Japanese patients with advanced heart failure, especially in the vulnerable post-discharge period.
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy